IMCR News and Press, Immunocore Holdings plc From 04/19/23

2023-04-19 04:36:59 ET Swiss biotech company developing novel T-cell receptor-based therapeutics, Engimmune Therapeutics AG ( NASDAQ: IMCR ) appoints Dr. Lars Nieba as CEO. Dr. Søren Mouritsen, co-founder and previous CEO, steps down in a planned transition. ...

Grey Wolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023 PR Newswire New Data Demonstrate Ability of ERAP1 Inhibition to Generate and Up...

Immunocore p resents new KIMMTRAK data confirm ing association between early ctDNA reduction and longer overall survival In the Phase 3 trial, early on-treatment ctDNA reduction was strongly as...

2023-04-16 05:54:31 ET Summary Two new Breakout Stocks for Week 16 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +55.1% YTD. Last week, peak gains were in BBW +10.37%, RNW +7.7%, TPBH +6.9%. The Active ETF portfolio ...

Immunocore to present at the 22 nd Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 April 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering th...

2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...

2023-03-31 11:37:54 ET U.K.-based biotech Immunocore Holdings ( NASDAQ: IMCR ) added ~4% on Friday after Mizuho Securities launched its coverage with a Buy recommendation calling the company "a leader in advancing T-cell receptor (TCR)-based therapies." In 2022, the FDA ...

Immunocore Holdings plc (IMCR) Q4 2022 Earnings Conference Call March 1, 2023 08:00 ET Company Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - Chief Executive Officer & Director Ralph Torbay - Head of Commercial Brian Di Donato - Chi...

Immunocore press release ( NASDAQ: IMCR ): FY GAAP EPS of -$1.09 misses by $0.62 . Revenue of $173.59M beats by $7.28M . For further details see: Immunocore GAAP EPS of -$1.09 misses by $0.62, revenue of $173.59M beats by $7.28M

Immunocore Reports 2022 Financial Results and Provides Business Update KIMMTRAK / tebentafusp net revenues of £ 42 million ($ 51 million) in Q4 2022 and £ 117 million ($ 141 million) in 2022 ; approved in ov...